Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,14667957,Css,"The mean (SD) Css of eptifibatide was essentially identical when it was coadministered with either UFH or enoxaparin (1640 [227] ng/mL and 1610 (229) ng/mL, respectively).",Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667957/),[ng] / [ml],1640,1032,DB01225,Enoxaparin
,14667957,Css,"The mean (SD) Css of eptifibatide was essentially identical when it was coadministered with either UFH or enoxaparin (1640 [227] ng/mL and 1610 (229) ng/mL, respectively).",Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14667957/),[ng] / [ml],1610,1033,DB01225,Enoxaparin
,11680668,oral clearance (CL),"The population estimates and 90% confidence intervals (CI) for oral clearance (CL) and apparent volume of distribution of the plasma compartment (Vc) were 0.0176 l/h/kg (CI = 0.012-0.023) and 0.098 l/kg (CI = 0.088 - 0.109), respectively.",Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),[l] / [h·kg],0.0176,2486,DB01225,Enoxaparin
,11680668,apparent volume of distribution of the plasma compartment (Vc),"The population estimates and 90% confidence intervals (CI) for oral clearance (CL) and apparent volume of distribution of the plasma compartment (Vc) were 0.0176 l/h/kg (CI = 0.012-0.023) and 0.098 l/kg (CI = 0.088 - 0.109), respectively.",Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),[l] / [kg],0.098,2487,DB01225,Enoxaparin
,11680668,elimination half-life,The elimination half-life was 3.9 h (CI = 2.5-5.2).,Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680668/),h,3.9,2488,DB01225,Enoxaparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],16.7,3377,DB01225,Enoxaparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],13.8,3378,DB01225,Enoxaparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],21.4,3379,DB01225,Enoxaparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],33.3,3380,DB01225,Enoxaparin
,7495071,apparent elimination half life t1/2,These differences in the disposition profiles explain why the apparent elimination half life t1/2 values of the LMMHs compared here are different: dalteparin: 2.8 h; nadroparin: 3.7 h; and enoxaparin: 4.1 h.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),h,2.8,3381,DB01225,Enoxaparin
,7495071,apparent elimination half life t1/2,These differences in the disposition profiles explain why the apparent elimination half life t1/2 values of the LMMHs compared here are different: dalteparin: 2.8 h; nadroparin: 3.7 h; and enoxaparin: 4.1 h.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),h,3.7,3382,DB01225,Enoxaparin
,7495071,apparent elimination half life t1/2,These differences in the disposition profiles explain why the apparent elimination half life t1/2 values of the LMMHs compared here are different: dalteparin: 2.8 h; nadroparin: 3.7 h; and enoxaparin: 4.1 h.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),h,4.1,3383,DB01225,Enoxaparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],2.29,6705,DB01225,Enoxaparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.99,6706,DB01225,Enoxaparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.58,6707,DB01225,Enoxaparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.36,6708,DB01225,Enoxaparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity (units/ml) 10 min and 2, 4, 6, and 8 hr after IV dose was 2.29 +/- 0.39, 0.99 +/- 0.29, 0.58 +/- 0.14, 0.36 +/- 0.13, 0.24 +/- 0.11, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),[units] / [ml],0.24,6709,DB01225,Enoxaparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.01,6710,DB01225,Enoxaparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.13,6711,DB01225,Enoxaparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.1,6712,DB01225,Enoxaparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,0.84,6713,DB01225,Enoxaparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,0.62,6714,DB01225,Enoxaparin
,12357518,Plasma anti-Xa activity,"Mean Plasma anti-Xa activity 2, 4, 6, 8, 10, and 12 hr after SC dose was 1.01 +/- 0.22, 1.13 +/- 0.27, 1.1 +/- 0.41, 0.84 +/- 0.19, 0.62 +/- 0.24, and 0.46 +/- 0.21, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,0.46,6715,DB01225,Enoxaparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity at the start and end of PCI was 1.27 +/- 0.41 and 1.07 +/- 0.42, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.27,6716,DB01225,Enoxaparin
,12357518,plasma anti-Xa activity,"Mean plasma anti-Xa activity at the start and end of PCI was 1.27 +/- 0.41 and 1.07 +/- 0.42, respectively.",Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357518/),,1.07,6717,DB01225,Enoxaparin
,21162606,bioavailability,The bioavailability of bemiparin was estimated at 96% and the apparent volume of distribution was 5.1 L.,Bemiparin: pharmacological profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),%,96,10989,DB01225,Enoxaparin
,21162606,apparent volume of distribution,The bioavailability of bemiparin was estimated at 96% and the apparent volume of distribution was 5.1 L.,Bemiparin: pharmacological profile. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),l,5.1,10990,DB01225,Enoxaparin
,21162606,half-life,Bemiparin has the longest half-life of all LMWH at 5.3 h compared with 0.5-1.0 h for unfractionated heparin.,Bemiparin: pharmacological profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),h,5.3,10991,DB01225,Enoxaparin
,21162606,half-life,Bemiparin has the longest half-life of all LMWH at 5.3 h compared with 0.5-1.0 h for unfractionated heparin.,Bemiparin: pharmacological profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),h,0.5-1.0,10992,DB01225,Enoxaparin
over,21162606,mean residence time,"Elimination is linear, with a mean residence time of over 7 h and total clearance of 0.9 L/h.",Bemiparin: pharmacological profile. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),h,7,10993,DB01225,Enoxaparin
,21162606,total clearance,"Elimination is linear, with a mean residence time of over 7 h and total clearance of 0.9 L/h.",Bemiparin: pharmacological profile. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21162606/),[l] / [h],0.9,10994,DB01225,Enoxaparin
,12845386,clearance,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),[ml] / [h·kg],10,24529,DB01225,Enoxaparin
,12845386,volume of distribution at steady state,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),[ml] / [kg],48,24530,DB01225,Enoxaparin
,12845386,volume of distribution at steady state,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),[ml] / [kg],45,24531,DB01225,Enoxaparin
,12845386,elimination rate constant,"Values for clearance, volume of distribution, volume of distribution at steady state, and elimination rate constant were on the order of 10 mL/h/kg, 48 mL/kg, 45 mL/kg, and 0.22/h, respectively.",Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845386/),1/[h],0.22,24532,DB01225,Enoxaparin
,28846877,Cmax24h,"The median anti-FXa Cmax24h was 0.05 (interquartile range, IQR, 0.05-0.18) IU/ml in the CII group and 0.18 (IQR, 0.12-0.33) IU/ml in the SCB group (p=0.05).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),[iu] / [ml],0.05,24893,DB01225,Enoxaparin
,28846877,Cmax24h,"The median anti-FXa Cmax24h was 0.05 (interquartile range, IQR, 0.05-0.18) IU/ml in the CII group and 0.18 (IQR, 0.12-0.33) IU/ml in the SCB group (p=0.05).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),[iu] / [ml],0.18,24894,DB01225,Enoxaparin
,28846877,AUC(0-24h),"Median anti-FXa AUC(0-24h) was 1.20 (IQR, 0.98-2.88) in the CII and 1.54 (IQR, 1.22-4.12) in the SCB group (p=0.095).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),,1.20,24895,DB01225,Enoxaparin
,28846877,AUC(0-24h),"Median anti-FXa AUC(0-24h) was 1.20 (IQR, 0.98-2.88) in the CII and 1.54 (IQR, 1.22-4.12) in the SCB group (p=0.095).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),,1.54,24896,DB01225,Enoxaparin
>,28846877,detectable anti-FXa concentration,"After 72h, 66.7% of patients in the CII group had a detectable anti-FXa concentration of >0.1IU/ml, compared with 16.7% in the SCB group (p=0.019).",Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28846877/),[iu] / [ml],0.1,24897,DB01225,Enoxaparin
<,23649851,F,"In vivo, oral Absorption at doses of 300 IU/kg was rather low (F < 2.5%) while dose increase resulted in a maximum at 600 IU/kg (FRL: 6.0 ± 1.2%; FRS: 5.8 ± 2.5%) and 1,200 IU/kg did not result in higher bioavailability (FRL: 4.6 ± 0.4%; FRS: 4.1 ± 0.8%).",Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649851/),%,2.5,33535,DB01225,Enoxaparin
,23649851,bioavaila,"In vivo, oral Absorption at doses of 300 IU/kg was rather low (F < 2.5%) while dose increase resulted in a maximum at 600 IU/kg (FRL: 6.0 ± 1.2%; FRS: 5.8 ± 2.5%) and 1,200 IU/kg did not result in higher bioavailability (FRL: 4.6 ± 0.4%; FRS: 4.1 ± 0.8%).",Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649851/),%,4.6,33536,DB01225,Enoxaparin
,23649851,bioavaila,"In vivo, oral Absorption at doses of 300 IU/kg was rather low (F < 2.5%) while dose increase resulted in a maximum at 600 IU/kg (FRL: 6.0 ± 1.2%; FRS: 5.8 ± 2.5%) and 1,200 IU/kg did not result in higher bioavailability (FRL: 4.6 ± 0.4%; FRS: 4.1 ± 0.8%).",Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649851/),%,4.1,33537,DB01225,Enoxaparin
,23649851,FRL,"In vivo, oral Absorption at doses of 300 IU/kg was rather low (F < 2.5%) while dose increase resulted in a maximum at 600 IU/kg (FRL: 6.0 ± 1.2%; FRS: 5.8 ± 2.5%) and 1,200 IU/kg did not result in higher bioavailability (FRL: 4.6 ± 0.4%; FRS: 4.1 ± 0.8%).",Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649851/),%,4.6,33538,DB01225,Enoxaparin
>,8707165,F,"Since they are mainly administered subcutaneously, then compared to UFH, they are almost completely absorbed (F > or = 90%) and, in contrast to UFH, those for which data are available in the literature exhibit linear pharmacokinetics with proportionality between anti-Xa (and anti-IIa in some cases) plasma concentration and dose, and stationary distribution volume and clearance processes when the dosage is increased.","Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8707165/),%,90,39903,DB01225,Enoxaparin
>,20139357,half-maximal inhibitory concentration [IC(50)],"It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (half-maximal inhibitory concentration [IC(50)], >20 micromol/L).",Rivaroxaban: a new oral factor Xa inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[μM] / [l],20,40475,DB01225,Enoxaparin
,20139357,inhibitory constant [K(i)],"Rivaroxaban inhibits factor Xa in a concentration-dependent manner (inhibitory constant [K(i)], 0.4 nmol/L) and binds rapidly (kinetic association rate constant [k(on)], 1.7x10(7) mol/L(-1) s(-1)) and reversibly (kinetic dissociation rate constant [k(off)], 5x10(-3) s(-1)).",Rivaroxaban: a new oral factor Xa inhibitor. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[nM] / [l],0.4,40476,DB01225,Enoxaparin
,20139357,kinetic association rate constant [k(on)],"Rivaroxaban inhibits factor Xa in a concentration-dependent manner (inhibitory constant [K(i)], 0.4 nmol/L) and binds rapidly (kinetic association rate constant [k(on)], 1.7x10(7) mol/L(-1) s(-1)) and reversibly (kinetic dissociation rate constant [k(off)], 5x10(-3) s(-1)).",Rivaroxaban: a new oral factor Xa inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[mol] / [l·s],1.7x10(7),40477,DB01225,Enoxaparin
,20139357,kinetic dissociation rate constant [k(off)],"Rivaroxaban inhibits factor Xa in a concentration-dependent manner (inhibitory constant [K(i)], 0.4 nmol/L) and binds rapidly (kinetic association rate constant [k(on)], 1.7x10(7) mol/L(-1) s(-1)) and reversibly (kinetic dissociation rate constant [k(off)], 5x10(-3) s(-1)).",Rivaroxaban: a new oral factor Xa inhibitor. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),1/[s],5x10(-3),40478,DB01225,Enoxaparin
,20139357,IC(50),"By inhibiting prothrombinase complex-bound (IC(50), 2.1 nmol/L) and clot-associated factor Xa (IC(50), 75 nmol/L), rivaroxaban reduces the thrombin burst during the propagation phase.",Rivaroxaban: a new oral factor Xa inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[nM] / [l],2.1,40479,DB01225,Enoxaparin
,20139357,IC(50),"By inhibiting prothrombinase complex-bound (IC(50), 2.1 nmol/L) and clot-associated factor Xa (IC(50), 75 nmol/L), rivaroxaban reduces the thrombin burst during the propagation phase.",Rivaroxaban: a new oral factor Xa inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139357/),[nM] / [l],75,40480,DB01225,Enoxaparin
,19446753,maximal plasma anti-Xa activities,"The highest maximal plasma anti-Xa activities and the highest bioavailabilities for enoxaparin granules (0.45+/-0.12IU/mL; 19.00+/-0.30%, respectively) and for bemiparin granules (0.54+/-0.08IU/mL; 29.02+/-4.12%, respectively) were found after oral administration of granules loaded with ERS alone at a dose of 600IU anti-Xa/kg to rabbits.",Granules in the improvement of oral heparin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446753/),[iu] / [ml],0.45,40968,DB01225,Enoxaparin
,19446753,maximal plasma anti-Xa activities,"The highest maximal plasma anti-Xa activities and the highest bioavailabilities for enoxaparin granules (0.45+/-0.12IU/mL; 19.00+/-0.30%, respectively) and for bemiparin granules (0.54+/-0.08IU/mL; 29.02+/-4.12%, respectively) were found after oral administration of granules loaded with ERS alone at a dose of 600IU anti-Xa/kg to rabbits.",Granules in the improvement of oral heparin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446753/),[iu] / [ml],0.54,40969,DB01225,Enoxaparin
,19446753,bioavailabilities,"The highest maximal plasma anti-Xa activities and the highest bioavailabilities for enoxaparin granules (0.45+/-0.12IU/mL; 19.00+/-0.30%, respectively) and for bemiparin granules (0.54+/-0.08IU/mL; 29.02+/-4.12%, respectively) were found after oral administration of granules loaded with ERS alone at a dose of 600IU anti-Xa/kg to rabbits.",Granules in the improvement of oral heparin bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446753/),%,19.00,40970,DB01225,Enoxaparin
,19446753,bioavailabilities,"The highest maximal plasma anti-Xa activities and the highest bioavailabilities for enoxaparin granules (0.45+/-0.12IU/mL; 19.00+/-0.30%, respectively) and for bemiparin granules (0.54+/-0.08IU/mL; 29.02+/-4.12%, respectively) were found after oral administration of granules loaded with ERS alone at a dose of 600IU anti-Xa/kg to rabbits.",Granules in the improvement of oral heparin bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446753/),%,29.02,40971,DB01225,Enoxaparin
,11144698,elimination half-life,"Pharmacokinetic parameters calculated from these concentrations using a one-compartment model were elimination half-life four hours, volume of distribution 0.13 L/kg, and clearance 0.022 L/kg/h.",Use of enoxaparin in a preterm infant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144698/),h,four,49676,DB01225,Enoxaparin
,11144698,volume of distribution,"Pharmacokinetic parameters calculated from these concentrations using a one-compartment model were elimination half-life four hours, volume of distribution 0.13 L/kg, and clearance 0.022 L/kg/h.",Use of enoxaparin in a preterm infant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144698/),[l] / [kg],0.13,49677,DB01225,Enoxaparin
,11144698,clearance,"Pharmacokinetic parameters calculated from these concentrations using a one-compartment model were elimination half-life four hours, volume of distribution 0.13 L/kg, and clearance 0.022 L/kg/h.",Use of enoxaparin in a preterm infant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144698/),[l] / [h·kg],0.022,49678,DB01225,Enoxaparin
,29977164,terminal half-life,"Betrixaban has the longest half-life among the DOAC class, with a terminal half-life of 35-45 h and an effective half-life of 19-27 h.",Pharmacological properties of betrixaban. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29977164/),h,35-45,53299,DB01225,Enoxaparin
,29977164,effective half-life,"Betrixaban has the longest half-life among the DOAC class, with a terminal half-life of 35-45 h and an effective half-life of 19-27 h.",Pharmacological properties of betrixaban. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29977164/),h,19-27,53300,DB01225,Enoxaparin
,15961985,peak anti-Xa activities,kg(-1) x 12 h(-)1 in patients with severe renal impairment should avoid accumulation of enoxaparin and keep peak anti-Xa activities between 0.5 and 1.2 IU/mL for a large majority of patients.,Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961985/),[iu] / [ml],0.5 and 1.2,54844,DB01225,Enoxaparin
,28267480,concentration,"The median concentration of betrixaban among subjects administered the 80-mg dose was higher than that of the 40-mg dose (19 ng/mL vs 11 ng/mL, P<.001).",The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28267480/),[ng] / [ml],11,60446,DB01225,Enoxaparin
,15850607,anti-Xa,"Mean (95% confidence interval (95% CI)) anti-Xa was equal to 1.14 IU/mL (1.07-1.21) and 1.14 IU/mL (1.08-1.20) among patients who received one (n=92) and two injections (n=122) per day, respectively.",Dosage of enoxaparin among obese and renal impairment patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850607/),[iu] / [ml],1.14,64532,DB01225,Enoxaparin
,15850607,anti-Xa,"Mean (95% confidence interval (95% CI)) anti-Xa was equal to 1.14 IU/mL (1.07-1.21) and 1.14 IU/mL (1.08-1.20) among patients who received one (n=92) and two injections (n=122) per day, respectively.",Dosage of enoxaparin among obese and renal impairment patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850607/),[iu] / [ml],1.14,64533,DB01225,Enoxaparin
,15850607,Anti,"Anti-Xa increases with body mass index (BMI) (0.01 IU/mL for each kg/m2; 95% CI: 0.002-0.017), but the increase is insufficient to reach supratherapeutic anti-Xa.",Dosage of enoxaparin among obese and renal impairment patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15850607/),[iu] / [ml],0.01,64534,DB01225,Enoxaparin
,25280062,anti,Six patients did not reach a therapeutic anti-Xa activity target (0.6-1.2 IU/ml) at 4 h after LMWH administration.,Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.6-1.2,67623,DB01225,Enoxaparin
,25280062,anti-factor Xa,Four patients did not reach anti-factor Xa values of 0.6 IU/ml throughout the trial.,Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.6,67624,DB01225,Enoxaparin
,25280062,anti-Xa activity,"The median anti-Xa activity before LMWH injection was 0.24 IU/ml (range 0.07-0.7 IU/ml), as opposed to 0.52 IU/ml in historical controls.",Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.24,67625,DB01225,Enoxaparin
,25280062,anti-Xa activity,"The median anti-Xa activity before LMWH injection was 0.24 IU/ml (range 0.07-0.7 IU/ml), as opposed to 0.52 IU/ml in historical controls.",Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.52,67626,DB01225,Enoxaparin
,25280062,anti-Xa activity,"The median anti-Xa activity 4 h after LMWH injection was 0.58 IU/ml (range 0.22-1.23 IU/ml), as opposed to 1.2 IU/ml in historical controls.",Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],0.58,67627,DB01225,Enoxaparin
,25280062,anti-Xa activity,"The median anti-Xa activity 4 h after LMWH injection was 0.58 IU/ml (range 0.22-1.23 IU/ml), as opposed to 1.2 IU/ml in historical controls.",Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25280062/),[iu] / [ml],1.2,67628,DB01225,Enoxaparin
,2851016,terminal half-lives,"The terminal half-lives of anti-IIa and anti-Xa activities were approximately 2 and 4 hours, respectively, with no significant variation between the different doses.","The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),h,2,75905,DB01225,Enoxaparin
,2851016,terminal half-lives,"The terminal half-lives of anti-IIa and anti-Xa activities were approximately 2 and 4 hours, respectively, with no significant variation between the different doses.","The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),h,4,75906,DB01225,Enoxaparin
,2851016,apparent volume of distribution,Enoxaparine displays a relatively small apparent volume of distribution (about 7.0 L) and its total body clearance is about 1.25 L/hr.,"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),l,7.0,75907,DB01225,Enoxaparin
,2851016,total body clearance,Enoxaparine displays a relatively small apparent volume of distribution (about 7.0 L) and its total body clearance is about 1.25 L/hr.,"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),[l] / [h],1.25,75908,DB01225,Enoxaparin
,2851016,mean residence time,The mean residence time ranges from 4.6 to 7.6 hours.,"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2851016/),h,4.6 to 7.6,75909,DB01225,Enoxaparin
,19954711,area under the curve (,"Bemiparin 3500 IU achieved more anti-Xa activity than enoxaparin 4000 IU, measured by the area under the curve (geometric mean AUC0t) (bemiparin 3.69 vs. enoxaparin 3.33 IU h/ml; p < 0.001).",Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),[h·iu] / [ml],3.69,81759,DB01225,Enoxaparin
,19954711,area under the curve (,"Bemiparin 3500 IU achieved more anti-Xa activity than enoxaparin 4000 IU, measured by the area under the curve (geometric mean AUC0t) (bemiparin 3.69 vs. enoxaparin 3.33 IU h/ml; p < 0.001).",Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),[h·iu] / [ml],3.33,81760,DB01225,Enoxaparin
,19954711,activity half-life,Anti-Xa activity half-life was 5.44 hours for bemiparin and 4.71 hours for enoxaparin.,Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),h,5.44,81761,DB01225,Enoxaparin
,19954711,activity half-life,Anti-Xa activity half-life was 5.44 hours for bemiparin and 4.71 hours for enoxaparin.,Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),h,4.71,81762,DB01225,Enoxaparin
,19954711,anti,"The ""in-vivo"" anti-Xa:IIa ratios were: bemiparin 37.9 (95% CI: 28.0 - 55.3, n = 2) and enoxaparin 16.3 (95% CI: 12.2 - 23.4, n = 8).",Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),,37,81763,DB01225,Enoxaparin
,19954711,anti,"The ""in-vivo"" anti-Xa:IIa ratios were: bemiparin 37.9 (95% CI: 28.0 - 55.3, n = 2) and enoxaparin 16.3 (95% CI: 12.2 - 23.4, n = 8).",Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19954711/),,16,81764,DB01225,Enoxaparin
,12532174,bioavailability,"Phase I trials have shown a 100% bioavailability after subcutaneous (s.c.) administration, a rapid onset of action and an approximate half-life of 13.5 h.",Fondaparinux sodium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532174/),%,100,83385,DB01225,Enoxaparin
,12532174,half-life,"Phase I trials have shown a 100% bioavailability after subcutaneous (s.c.) administration, a rapid onset of action and an approximate half-life of 13.5 h.",Fondaparinux sodium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532174/),h,13.5,83386,DB01225,Enoxaparin
,26766749,LOS,"The median (range) LOS was 7 (2-58) days for the compliant group versus 15 days (2-101) for the noncompliant (P = 0.06, Mann-Whitney U test).",Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26766749/),d,7,87329,DB01225,Enoxaparin
,26766749,LOS,"The median (range) LOS was 7 (2-58) days for the compliant group versus 15 days (2-101) for the noncompliant (P = 0.06, Mann-Whitney U test).",Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26766749/),d,15,87330,DB01225,Enoxaparin
,26766749,LOS,"In these patients, the median (range) LOS was 16.5 days (2-101).",Compliance With Enoxaparin Dosing and Monitoring Guidelines and the Impact on Patient Length of Stay: A Pilot Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26766749/),d,16.5,87331,DB01225,Enoxaparin
<,25900127,anti-Xa activities,The clinical study reconfirmed the absence of bioaccumulation of certoparin with anti-Xa activities between <0.01 and 0.02 IU/mL after 24 h.,Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25900127/),[iu] / [ml],0.,87392,DB01225,Enoxaparin
,25900127,plasma half-life time,A short plasma half-life time of 2.0 ± 0.7 h was determined during hemodialysis.,Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25900127/),h,2.0,87393,DB01225,Enoxaparin
,25900127,half-life time,"Different from LMWH significantly cleared by the kidneys, the relatively short half-life time of certoparin of only 2 h during hemodialysis allows a more reliable control of the anti-coagulatory effects and decreases the risk of bleeding complications.",Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25900127/),h,2,87394,DB01225,Enoxaparin
,19066002,bioavailability,"After oral administration the absorption is near 100%, the bioavailability is near 80%, and the elimination half-life is 5-9 hours with mixed excretion via the renal and fecal/biliary routes.",New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19066002/),%,80,88857,DB01225,Enoxaparin
,19066002,elimination half-life,"After oral administration the absorption is near 100%, the bioavailability is near 80%, and the elimination half-life is 5-9 hours with mixed excretion via the renal and fecal/biliary routes.",New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19066002/),h,5-9,88858,DB01225,Enoxaparin
,27628785,en,"By incorporation of the negative polymer of enoxaparin sodium (ES), DOX was highly encapsulated into EPNs with an encapsulation efficiency of 92.49%, and ES effectively inhibited the proliferation of HUVEC cell lines.",Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27628785/),,92,91236,DB01225,Enoxaparin
outside,16842391,percentage of,To develop an appropriate dosing strategy for continuous intravenous infusions (CII) of enoxaparin by minimizing the percentage of steady-state anti-Xa concentration (C(ss)) outside the therapeutic range of 0.5-1.2 IU ml(-1).,Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842391/),[iu] / [ml],0.5-1.2,93402,DB01225,Enoxaparin
outside,16842391,steady-state anti-Xa concentration (C(ss)),To develop an appropriate dosing strategy for continuous intravenous infusions (CII) of enoxaparin by minimizing the percentage of steady-state anti-Xa concentration (C(ss)) outside the therapeutic range of 0.5-1.2 IU ml(-1).,Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842391/),[iu] / [ml],0.5-1.2,93403,DB01225,Enoxaparin
,19272635,peak anti-Xa level,"The average peak anti-Xa level was 0.25 (SD+/-0.11, range 0.08 to 0.59) units/mL.","Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19272635/),[units] / [ml],0.25,97212,DB01225,Enoxaparin
,20298591,AFXa,An AFXa level between 0.1 to 0.3 IU/ml was considered evidence of effective antithrombotic activity.,"Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20298591/),[iu] / [ml],0.1 to 0.3,98134,DB01225,Enoxaparin
,16291417,Sc,Mean Sc (for CVVH) or Sa (for CVVHD) values in the in vitro procedures ranged from 0.16 to 0.57.,In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.,109942,DB01225,Enoxaparin
,16291417,Sa,Mean Sc (for CVVH) or Sa (for CVVHD) values in the in vitro procedures ranged from 0.16 to 0.57.,In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.,109943,DB01225,Enoxaparin
,16291417,Sc,"In patients, Sc or Sa achieved values between 0.26 and 0.67.",In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.26,109944,DB01225,Enoxaparin
,16291417,Sa,"In patients, Sc or Sa achieved values between 0.26 and 0.67.",In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.26,109945,DB01225,Enoxaparin
,16291417,Sa,"In patients, Sc or Sa achieved values between 0.26 and 0.67.",In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291417/),,0.67,109946,DB01225,Enoxaparin
below,21454037,Anti-Xa,Anti-Xa levels below 0.1 IU/mL at any time were considered subtherapeutic.,Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454037/),[iu] / [ml],0.1,116409,DB01225,Enoxaparin
more,21454037,anti-Xa,Two patients (5.6%) did not attain therapeutic levels defined as anti-Xa more than 0.1 IU/mL at 3 hours post dose.,Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454037/),[iu] / [ml],0.1,116410,DB01225,Enoxaparin
,21454037,AUC,"Median AUC was 1.84 IU·h/mL (interquartile range, 1.47 IU·h/mL).",Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454037/),[h·iu] / [ml],1.84,116411,DB01225,Enoxaparin
more,21454037,anti-Xa level,"In the study, prophylactic SC enoxaparin in critically ill patients at the current 30 mg SC twice daily dosage attained an anti-Xa level more than 0.1 U/mL in nearly all patients.",Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21454037/),[u] / [ml],0.1,116412,DB01225,Enoxaparin
,12383040,terminal half-life,"It has favourable pharmacokinetics including 100% bioavailability, low variability and a mean terminal half-life of 17 hours for young and 21 hours for elderly healthy volunteers, enabling once-daily administration.",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),h,17,121095,DB01225,Enoxaparin
,12383040,terminal half-life,"It has favourable pharmacokinetics including 100% bioavailability, low variability and a mean terminal half-life of 17 hours for young and 21 hours for elderly healthy volunteers, enabling once-daily administration.",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),h,21,121096,DB01225,Enoxaparin
,12383040,B(max),"The specific binding parameters B(max) (binding capacity) and K(D )(dissociation constant) were similar for human plasma (B(max) = 2072 nmol/L, K(D) = 28 nmol/L) and purified ATIII (B(max) = 1627 nmol/L and K(D) = 32 nmol/L).",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),[nM] / [l],2072,121097,DB01225,Enoxaparin
,12383040,K(D),"The specific binding parameters B(max) (binding capacity) and K(D )(dissociation constant) were similar for human plasma (B(max) = 2072 nmol/L, K(D) = 28 nmol/L) and purified ATIII (B(max) = 1627 nmol/L and K(D) = 32 nmol/L).",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),[nM] / [l],28,121098,DB01225,Enoxaparin
,12383040,B(max),"The specific binding parameters B(max) (binding capacity) and K(D )(dissociation constant) were similar for human plasma (B(max) = 2072 nmol/L, K(D) = 28 nmol/L) and purified ATIII (B(max) = 1627 nmol/L and K(D) = 32 nmol/L).",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),[nM] / [l],1627,121099,DB01225,Enoxaparin
,12383040,K(D),"The specific binding parameters B(max) (binding capacity) and K(D )(dissociation constant) were similar for human plasma (B(max) = 2072 nmol/L, K(D) = 28 nmol/L) and purified ATIII (B(max) = 1627 nmol/L and K(D) = 32 nmol/L).",Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12383040/),[nM] / [l],32,121100,DB01225,Enoxaparin
,14980001,duration of action,The reversibility study with dodecanoylsucrose showed that the effect of alkanoylsucroses faded away with time and the duration of action of this agent at the site of administration was 120-140 min.,Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14980001/),min,120-140,121404,DB01225,Enoxaparin
,8703665,Amax,"The Amax and the AUC(0, 24h) of plasma anti-Xa activity after reviparin administration were both slightly but significantly lower than those observed after enoxaparin administration (difference between treatments of 0.03 95% CI[0.01-0.05] iu ml-1 h and 0.56 95% CI[0.22-0.90] iu ml-1 for Amax and AUC(0, 24h) respectively).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),[h·iu] / [ml],0.03,123382,DB01225,Enoxaparin
,8703665,Amax,"The Amax and the AUC(0, 24h) of plasma anti-Xa activity after reviparin administration were both slightly but significantly lower than those observed after enoxaparin administration (difference between treatments of 0.03 95% CI[0.01-0.05] iu ml-1 h and 0.56 95% CI[0.22-0.90] iu ml-1 for Amax and AUC(0, 24h) respectively).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),[iu] / [ml],0.56,123383,DB01225,Enoxaparin
,8703665,"AUC(0, 24h)","The Amax and the AUC(0, 24h) of plasma anti-Xa activity after reviparin administration were both slightly but significantly lower than those observed after enoxaparin administration (difference between treatments of 0.03 95% CI[0.01-0.05] iu ml-1 h and 0.56 95% CI[0.22-0.90] iu ml-1 for Amax and AUC(0, 24h) respectively).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),[iu] / [ml],0.56,123384,DB01225,Enoxaparin
,8703665,t1/2,"The t1/2 for reviparin did not significantly differ from that of enoxaparin (2.7 +/- 0.7 h vs 3.5 +/- 0.9 h respectively, NS).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),h,2.7,123385,DB01225,Enoxaparin
,8703665,t1/2,"The t1/2 for reviparin did not significantly differ from that of enoxaparin (2.7 +/- 0.7 h vs 3.5 +/- 0.9 h respectively, NS).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),h,3.5,123386,DB01225,Enoxaparin
,8703665,Amax,"The Amax of the plasma anti-thrombin activity after reviparin administration was also slightly but significantly lower than that observed after enoxaparin administration, (difference between treatments of 0.018 95% CI[0.01-0.025] iu ml-1) whereas the AUC(0, 24h) of anti-thrombin activity vs time was not.",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),[iu] / [ml],0.018,123387,DB01225,Enoxaparin
,8703665,surface under the thrombin generation curve,"4. The calculated surface under the thrombin generation curve vs time (or thrombin potential) at peak was significantly higher after reviparin than after enoxaparin (367 +/- 53 UA vs 305 +/- 48 UA respectively, P < 0.05).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),ua,367,123388,DB01225,Enoxaparin
,8703665,surface under the thrombin generation curve,"4. The calculated surface under the thrombin generation curve vs time (or thrombin potential) at peak was significantly higher after reviparin than after enoxaparin (367 +/- 53 UA vs 305 +/- 48 UA respectively, P < 0.05).",Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8703665/),ua,305,123389,DB01225,Enoxaparin
,11213853,total body clearance,"After administration of the drug, total body clearance was 14.6 ml/minute and there was a 2-fold prolongation in antifactor Xa activity half-life compared with values reported in healthy subjects.",The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213853/),[ml] / [min],14.6,130714,DB01225,Enoxaparin
,11213853,accumulation ratio,An accumulation ratio of 1.6 was estimated for a dosing interval of every 12 hours based on single-dose pharmacokinetics.,The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11213853/),,1.6,130715,DB01225,Enoxaparin
,15454859,Ki,"PD-198961, 3-(4-5-[(2R,6S)-2,6-dimethyltetrahydro-1(2H)-pyridinyl]pentyl-3-oxo-3,4-dihydro-2-quinoxalinyl)-4-hydroxybenzenecarboximidamide, is a novel, synthetic factor Xa inhibitor with a Ki of 2.7 nM against human factor Xa.","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),nM,2.7,133120,DB01225,Enoxaparin
,15454859,peak plasma concentration,The peak plasma concentration of PD-198961 was 977 +/- 96 ng/ml.,"In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),[ng] / [ml],977,133121,DB01225,Enoxaparin
,15454859,TTO,"When administered at 3.0 microg/kg/min IV, PD-198961 prolonged TTO from 28 +/- 5 minutes (control) to 120 +/- 0 minutes (P < 0.001) and reduced TW from 9.9 +/- 1.5 mg (control) to 2.8 +/- 0.9 mg (P < 0.01).","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),min,28,133122,DB01225,Enoxaparin
,15454859,TTO,"When administered at 3.0 microg/kg/min IV, PD-198961 prolonged TTO from 28 +/- 5 minutes (control) to 120 +/- 0 minutes (P < 0.001) and reduced TW from 9.9 +/- 1.5 mg (control) to 2.8 +/- 0.9 mg (P < 0.01).","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),min,120,133123,DB01225,Enoxaparin
,15454859,TW,"When administered at 3.0 microg/kg/min IV, PD-198961 prolonged TTO from 28 +/- 5 minutes (control) to 120 +/- 0 minutes (P < 0.001) and reduced TW from 9.9 +/- 1.5 mg (control) to 2.8 +/- 0.9 mg (P < 0.01).","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),mg,9.9,133124,DB01225,Enoxaparin
,15454859,TW,"When administered at 3.0 microg/kg/min IV, PD-198961 prolonged TTO from 28 +/- 5 minutes (control) to 120 +/- 0 minutes (P < 0.001) and reduced TW from 9.9 +/- 1.5 mg (control) to 2.8 +/- 0.9 mg (P < 0.01).","In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454859/),mg,2.8,133125,DB01225,Enoxaparin
,12598065,IC(50)s,"Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected.","Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598065/),[μM] / [l],0.376,136505,DB01225,Enoxaparin
,12598065,IC(50)s,"Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected.","Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598065/),[μM] / [l],0.163,136506,DB01225,Enoxaparin
,12598065,IC(50)s,"Statistically significant concentration (melagatran, the active form of ximelagatran)-response relationships for F1+2 (p = 0.005), TAT (p = 0.005) and beta-TG (p < 0.001) levels, with IC(50)s of 0.376 (F1+2), 0.163 (TAT) and 0.115 (beta-TG) micromol/l, were detected.","Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598065/),[μM] / [l],0.115,136507,DB01225,Enoxaparin
,12968985,clearance,"Basic population PK parameters were an enoxaparin clearance of 0.733 l h(-1)[95% confidence interval (CI) 0.698, 0.738], a distribution volume of 5.24 l (95% CI 4.20, 6.28) and an elimination half-life of 5.0 h.",Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968985/),[l] / [h],0.733,141796,DB01225,Enoxaparin
,12968985,distribution volume,"Basic population PK parameters were an enoxaparin clearance of 0.733 l h(-1)[95% confidence interval (CI) 0.698, 0.738], a distribution volume of 5.24 l (95% CI 4.20, 6.28) and an elimination half-life of 5.0 h.",Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968985/),l,5.24,141797,DB01225,Enoxaparin
,12968985,elimination half-life,"Basic population PK parameters were an enoxaparin clearance of 0.733 l h(-1)[95% confidence interval (CI) 0.698, 0.738], a distribution volume of 5.24 l (95% CI 4.20, 6.28) and an elimination half-life of 5.0 h.",Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968985/),h,5.0,141798,DB01225,Enoxaparin
,31463801,Peak plasma anti-FXa activity (Cmax),"Peak plasma anti-FXa activity (Cmax) ranged from 0.14 to 0.30 IU/mL, median Cmax was 0.205 IU/mL.",Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463801/),[iu] / [ml],0.14 to 0.30,142170,DB01225,Enoxaparin
,31463801,Cmax,"Peak plasma anti-FXa activity (Cmax) ranged from 0.14 to 0.30 IU/mL, median Cmax was 0.205 IU/mL.",Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463801/),[iu] / [ml],0.205,142171,DB01225,Enoxaparin
,31463801,Tmax,Median Tmax was 5.67 h (range 3.78-7.52 h).,Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463801/),h,5.67,142172,DB01225,Enoxaparin
,31463801,AUCi,Median AUCi was 1.00 h IU/mL (range 0.42-1.67 h IU/mL).,Prophylactic Use of Enoxaparin in Adolescents During Bariatric Surgery-a Prospective Clinical Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31463801/),[h·iu] / [ml],1.00,142173,DB01225,Enoxaparin
,30463865,anti,"Utilizing standard population pharmacokinetic data, the expected antifactor Xa activity without TPE was 0.14 IU/mL.",Effect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30463865/),[iu] / [ml],0.14,142888,DB01225,Enoxaparin
,26068539,Oral bioavailability,Oral bioavailability is 62% in healthy subjects and the terminal half-life is approximately 10-14 h.,Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068539/),%,62,146120,DB01225,Enoxaparin
,26068539,terminal half-life,Oral bioavailability is 62% in healthy subjects and the terminal half-life is approximately 10-14 h.,Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068539/),h,10-14,146121,DB01225,Enoxaparin
,27044828,polydispersity index,"The polydispersity index of NG-LMWH was 1.052, which was lower than heparin (1.5) and enoxaparin (1.279).",Preparation and evaluation a new generation of low molecular weight heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044828/),,1.052,147575,DB01225,Enoxaparin
,27044828,polydispersity index,"The polydispersity index of NG-LMWH was 1.052, which was lower than heparin (1.5) and enoxaparin (1.279).",Preparation and evaluation a new generation of low molecular weight heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044828/),,1.5,147576,DB01225,Enoxaparin
,27044828,polydispersity index,"The polydispersity index of NG-LMWH was 1.052, which was lower than heparin (1.5) and enoxaparin (1.279).",Preparation and evaluation a new generation of low molecular weight heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044828/),,1.279,147577,DB01225,Enoxaparin
,2847460,clearance half-life,After intravenous and sub-cutaneous injection the clearance half-life of the different LMW heparins is about 3 to 4 hours.,Pharmacokinetics of low molecular weight heparins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2847460/),h,3 to 4,149278,DB01225,Enoxaparin
,25087072,anti-Xa,The primary objective was to determine if modified enoxaparin treatment doses would achieve therapeutic anti-Xa levels (goal range 0.6-1.0 IU/mL) in morbidly obese patients.,Assessing an enoxaparin dosing protocol in morbidly obese patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25087072/),i,0.6-1.0,150465,DB01225,Enoxaparin
,25087072,anti-Xa level,The initial peak anti-Xa levels were in therapeutic range in 15 of 31 patients (48 %) with an initial mean anti-Xa level of 0.92 IU/mL.,Assessing an enoxaparin dosing protocol in morbidly obese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25087072/),[iu] / [ml],0.92,150466,DB01225,Enoxaparin
,16187968,CL,"Mean population parameters (intersubject variability, %) were CL 1.2 l h(-1) (33), V 2.9 l (30) and zero-order input 0.25 h (24).",Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187968/),[l] / [h],1.2,156480,DB01225,Enoxaparin
,16187968,V,"Mean population parameters (intersubject variability, %) were CL 1.2 l h(-1) (33), V 2.9 l (30) and zero-order input 0.25 h (24).",Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187968/),l,2.9,156481,DB01225,Enoxaparin
,16187968,zero-order input,"Mean population parameters (intersubject variability, %) were CL 1.2 l h(-1) (33), V 2.9 l (30) and zero-order input 0.25 h (24).",Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187968/),h,0.25,156482,DB01225,Enoxaparin
>,16187968,anti-Xa,"With a single bolus of 0.5 mg kg(-1), the totality of the patients reached an effective anticoagulation level (anti-Xa >0.5 IU ml(-1)) and only 2.5% reached levels above 1.5 IU ml(-1).",Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187968/),[iu] / [ml],0.5,156483,DB01225,Enoxaparin
,23899618,inhibition constants,"LB30870 was more potent than melagatran or argatroban with thrombin inhibition constants of 0.02, 1.3 and 4.5 nM, respectively.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),nM,0.02,158804,DB01225,Enoxaparin
,23899618,inhibition constants,"LB30870 was more potent than melagatran or argatroban with thrombin inhibition constants of 0.02, 1.3 and 4.5 nM, respectively.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),nM,1.3,158805,DB01225,Enoxaparin
,23899618,inhibition constants,"LB30870 was more potent than melagatran or argatroban with thrombin inhibition constants of 0.02, 1.3 and 4.5 nM, respectively.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),nM,4.5,158806,DB01225,Enoxaparin
greater,23899618,selectivity ratio,"All three direct thrombin inhibitors were selective towards other serine proteases with selectivity ratio greater than 1000, except for trypsin.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),,1000,158807,DB01225,Enoxaparin
,23899618,ED50,"The ED50 of LB30870, melagatran and enoxaparin were 50 μg/kg+2 μg/kg/min, 35 μg/kg+1.4 μg/kg/min and 200 μg/kg+8.3 μg/kg/min, respectively.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),[μg] / [kg],50,158808,DB01225,Enoxaparin
,23899618,ED50,"The ED50 of LB30870, melagatran and enoxaparin were 50 μg/kg+2 μg/kg/min, 35 μg/kg+1.4 μg/kg/min and 200 μg/kg+8.3 μg/kg/min, respectively.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),[μg] / [kg·min],2,158809,DB01225,Enoxaparin
,23899618,ED50,"The ED50 of LB30870, melagatran and enoxaparin were 50 μg/kg+2 μg/kg/min, 35 μg/kg+1.4 μg/kg/min and 200 μg/kg+8.3 μg/kg/min, respectively.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),[μg] / [kg],35,158810,DB01225,Enoxaparin
,23899618,ED50,"The ED50 of LB30870, melagatran and enoxaparin were 50 μg/kg+2 μg/kg/min, 35 μg/kg+1.4 μg/kg/min and 200 μg/kg+8.3 μg/kg/min, respectively.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),[μg] / [kg·min],1.4,158811,DB01225,Enoxaparin
,23899618,ED50,"The ED50 of LB30870, melagatran and enoxaparin were 50 μg/kg+2 μg/kg/min, 35 μg/kg+1.4 μg/kg/min and 200 μg/kg+8.3 μg/kg/min, respectively.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),[μg] / [kg],200,158812,DB01225,Enoxaparin
,23899618,ED50,"The ED50 of LB30870, melagatran and enoxaparin were 50 μg/kg+2 μg/kg/min, 35 μg/kg+1.4 μg/kg/min and 200 μg/kg+8.3 μg/kg/min, respectively.","Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23899618/),[μg] / [kg·min],8.3,158813,DB01225,Enoxaparin
,18431408,Clearance,"Clearance of the drug was higher in the pregnant women throughout pregnancy when compared with nonpregnant women (0.78 +/- 0.03 l/h vs. 0.52 +/- 0.03 l/h, respectively P < 0.001) with the stage of the pregnancy having no influence.",Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18431408/),[l] / [h],0.78,160244,DB01225,Enoxaparin
,18431408,Clearance,"Clearance of the drug was higher in the pregnant women throughout pregnancy when compared with nonpregnant women (0.78 +/- 0.03 l/h vs. 0.52 +/- 0.03 l/h, respectively P < 0.001) with the stage of the pregnancy having no influence.",Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18431408/),[l] / [h],0.52,160245,DB01225,Enoxaparin
,12235452,Time to maximum anti-Xa activity,"Time to maximum anti-Xa activity was 1 hour longer in obese volunteers, but maximum anti-Xa activity was similar in both groups.",The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235452/),h,1,178920,DB01225,Enoxaparin
,28962537,anti,"A median of 3 (IQR = 1-5) anti-factor Xa levels were sampled at 4.4 ± 1.3 hours after a dose, with a mean anti-factor Xa level of 0.52 ± 0.23 U/mL.",Population Pharmacokinetics of Enoxaparin in Pediatric Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28962537/),u,0.52,183740,DB01225,Enoxaparin
,31116389,peak aFXa levels,"Primary outcome: in-range peak aFXa levels (goal range, 0.3-0.5 IU/mL) with enoxaparin, 40 mg per day.",Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31116389/),[iu] / [ml],0.3-0.5,187182,DB01225,Enoxaparin
,31116389,trough aFXa,"Secondary outcomes: (1) in-range trough aFXa levels (goal range, 0.1-0.2 IU/mL) and (2) the proportion of patients with in-range peak aFXa levels from enoxaparin, 40 mg once daily, vs the real-time enoxaparin dose adjustment protocol.",Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31116389/),[iu] / [ml],0.1-0.2,187183,DB01225,Enoxaparin
<,31116389,aFXa,"Among 106 patients (91.4%) whose peak aFXa level was appropriately drawn, 72 (67.9%) received inadequate anticoagulation (aFXa < 0.3 IU/mL) with enoxaparin, 40 mg per day.",Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31116389/),[iu] / [ml],0.3,187184,DB01225,Enoxaparin
,19929210,relative bioavailabilities,"Enoxaparin pellets showed fast in vitro release in phosphate buffer (pH 7.4) and prolonged in vivo drug absorption after a single oral dose of 600 anti-Xa IU/ kg of body weight, leading to relative bioavailabilities ranging from 9.7 +/- 1.9% to 12.8 +/- 2.7% and anti-Xa activity over the curative dose.",Pellets for oral administration of low-molecular-weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19929210/),%,9.7,189138,DB01225,Enoxaparin
,19929210,relative bioavailabilities,"Enoxaparin pellets showed fast in vitro release in phosphate buffer (pH 7.4) and prolonged in vivo drug absorption after a single oral dose of 600 anti-Xa IU/ kg of body weight, leading to relative bioavailabilities ranging from 9.7 +/- 1.9% to 12.8 +/- 2.7% and anti-Xa activity over the curative dose.",Pellets for oral administration of low-molecular-weight heparin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19929210/),%,12.8,189139,DB01225,Enoxaparin
,20586920,clearance,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),h⁻¹·kg⁻¹·ml,15,196788,DB01225,Enoxaparin
,20586920,central volume of distribution,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),kg⁻¹·ml,169,196789,DB01225,Enoxaparin
,20586920,intercompartmental clearance,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),h⁻¹·ml,58,196790,DB01225,Enoxaparin
,20586920,peripheral volume of distribution,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),l,10,196791,DB01225,Enoxaparin
,20586920,absorption rate,"Body weight proved to be the most predictive covariate for clearance and central volume of distribution: clearance 15 mL h⁻¹ kg⁻¹, central volume of distribution 169 mL kg⁻¹, intercompartmental clearance 58 mL h⁻¹, peripheral volume of distribution 10 L and absorption rate 0.414 h⁻¹.","Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),h⁻¹,0.414,196792,DB01225,Enoxaparin
above,20586920,24 h,In 53.2% of the patients the median 24 h trough level was above the desired range of 0.1 IU mL⁻¹ anti-FXa activity for prophylaxis therapy.,"Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),iu·ml⁻¹,0.1,196793,DB01225,Enoxaparin
above,20586920,trough level,In 53.2% of the patients the median 24 h trough level was above the desired range of 0.1 IU mL⁻¹ anti-FXa activity for prophylaxis therapy.,"Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20586920/),iu·ml⁻¹,0.1,196794,DB01225,Enoxaparin
,12904065,K(i),"We conducted optimization of a highly efficacious benzamidine-based thrombin inhibitor LB30812 (3, K(i) = 3 pM) to improve oral bioavailability.","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),pM,3,202105,DB01225,Enoxaparin
,12904065,K(i),"The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively).","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),pM,15,202106,DB01225,Enoxaparin
,12904065,F,"The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively).","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),%,43,202107,DB01225,Enoxaparin
,12904065,F,"The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively).","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),%,42,202108,DB01225,Enoxaparin
,12904065,F,"The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively).","Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12904065/),%,15,202109,DB01225,Enoxaparin
,27693677,droplet size,"The average droplet size of chosen LC-SEDDS, MC-SEDDS and NL-SEDDS ranged between 30 and 40nm.","Development, in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27693677/),nm,30 and 40,202337,DB01225,Enoxaparin
,27693677,bioavailability,"Furthermore, orally administrated MC-SEDDS and NL-SEDDS yielded an absolute enoxaparin bioavailability of 2.02% and 2.25%, respectively.","Development, in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27693677/),%,2.02,202338,DB01225,Enoxaparin
,27693677,bioavailability,"Furthermore, orally administrated MC-SEDDS and NL-SEDDS yielded an absolute enoxaparin bioavailability of 2.02% and 2.25%, respectively.","Development, in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27693677/),%,2.25,202339,DB01225,Enoxaparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.2,205686,DB01225,Enoxaparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.38,205687,DB01225,Enoxaparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.54,205688,DB01225,Enoxaparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.26,205689,DB01225,Enoxaparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.40,205690,DB01225,Enoxaparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.64,205691,DB01225,Enoxaparin
,15459586,anti-Xa level,The mean +/- SD [95% CI] anti-Xa level 4 hours after the third dose was 0.65 +/- 0.19 [0.59 to 0.70] IU/mL for the severe group and 0.82 +/- 0.18 [0.79 to 0.85] IU/mL for the moderate group (P <.001).,Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15459586/),[iu] / [ml],0.65,206345,DB01225,Enoxaparin
,15459586,anti-Xa level,The mean +/- SD [95% CI] anti-Xa level 4 hours after the third dose was 0.65 +/- 0.19 [0.59 to 0.70] IU/mL for the severe group and 0.82 +/- 0.18 [0.79 to 0.85] IU/mL for the moderate group (P <.001).,Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15459586/),[iu] / [ml],0.82,206346,DB01225,Enoxaparin
,15081569,lag phase,"Ximelagatran (30 mg, 3.79 min, 3.52-4.08 at 2 h), r-hirudin (6.23 min, 4.93-7.86 at 2 h), and enoxaparin (4.68 min, 3.30-6.64 at 2 h) also delayed the lag phase before the thrombin generation burst compared to placebo (2.92 min, 2.71-3.25 at 2 h).","The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081569/),min,2.92,206793,DB01225,Enoxaparin
,15752373,fraction of drug excreted unchanged (Fu),The fraction of drug excreted unchanged (Fu) was estimated at 71%.,Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752373/),%,71,207439,DB01225,Enoxaparin
higher,14551364,anti-Xa activity,"A single injection of enoxaparin at 60 U IU/kg (4000 +/- 455 IU) led to an anti-Xa activity higher than 1.2 IU/ml during the first 2 h of the session, and between 0.4 and 1.2 IU during the third and fourth hours.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),[iu] / [ml],1.2,218874,DB01225,Enoxaparin
,14551364,anti-Xa activity,"A single injection of enoxaparin at 60 U IU/kg (4000 +/- 455 IU) led to an anti-Xa activity higher than 1.2 IU/ml during the first 2 h of the session, and between 0.4 and 1.2 IU during the third and fourth hours.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),iu,0.4 and 1.2,218875,DB01225,Enoxaparin
higher,14551364,anti-Xa activity,"After the end of the session, anti-Xa activity remained higher than 0.4 IU/ml up to 10 h after injection, and higher than 0.1 IU/ml up to 24 h.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),[iu] / [ml],0.4,218876,DB01225,Enoxaparin
higher,14551364,anti-Xa activity,"After the end of the session, anti-Xa activity remained higher than 0.4 IU/ml up to 10 h after injection, and higher than 0.1 IU/ml up to 24 h.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),[iu] / [ml],0.1,218877,DB01225,Enoxaparin
>,14551364,anti-Xa activity,"Whatever the procedure, anti-Xa activity remained high (>0.22 +/- 0.99 UI/ml) up to 12 h after the start of the dialysis session.",Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551364/),[ui] / [ml],0.22,218878,DB01225,Enoxaparin
,17552440,anti-Xa activity,"Mean anti-Xa activity 4 hours after enoxaparin (0.48 U/mL) approached the human therapeutic target (0.5-1.0 U/mL); however, mean trough anti-Xa activity was below detection limits.",Anticoagulant effects of low-molecular-weight heparins in healthy cats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17552440/),[u] / [ml],0.48,231882,DB01225,Enoxaparin
,17552440,anti-Xa activity,"Mean anti-Xa activity 4 hours after enoxaparin (0.48 U/mL) approached the human therapeutic target (0.5-1.0 U/mL); however, mean trough anti-Xa activity was below detection limits.",Anticoagulant effects of low-molecular-weight heparins in healthy cats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17552440/),[u] / [ml],0.5-1.0,231883,DB01225,Enoxaparin
,15167633,clearance (CL/F),"The mean clearance (CL/F) and distribution volume (V/F) were 0.72 L/h and 6.65 L, respectively.",Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),[l] / [h],0.72,235107,DB01225,Enoxaparin
,15167633,distribution volume (V/F),"The mean clearance (CL/F) and distribution volume (V/F) were 0.72 L/h and 6.65 L, respectively.",Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),l,6.65,235108,DB01225,Enoxaparin
,15167633,elimination half-life,"The elimination half-life was thus estimated to be 6.4 and 9.2 hours in male and female patients, respectively.",Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),h,6.4,235109,DB01225,Enoxaparin
,15167633,elimination half-life,"The elimination half-life was thus estimated to be 6.4 and 9.2 hours in male and female patients, respectively.",Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),h,9.2,235110,DB01225,Enoxaparin
above,15167633,Maximal anti-Xa activity,Maximal anti-Xa activity was predicted to rise above 1.5 IU/mL in case of mild elevation of serum creatinine according to gender and body weight.,Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167633/),[iu] / [ml],1.5,235111,DB01225,Enoxaparin
,32045583,peak anti-factor Xa,"Weight-tiered enoxaparin was not significantly more likely to produce adequate anticoagulation (peak anti-factor Xa 0.3 IU/mL or greater) when compared with fixed-dose enoxaparin (44.3% vs 48.2%, P = .67).",Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32045583/),[iu] / [ml],0.3,235506,DB01225,Enoxaparin
,32045583,peak anti-factor Xa,"Weight-tiered enoxaparin was not more likely to avoid over-anticoagulation (peak anti-factor Xa 0.5 IU/mL or greater) when compared with fixed-dose enoxaparin (3.3% vs 3.6%, P = 1.00).",Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32045583/),[iu] / [ml],0.5,235507,DB01225,Enoxaparin
,22398784,peak pharmacodynamic effect,"Average peak pharmacodynamic effect, measured by anti-Xa activity, was 1.36 U/ml after administration of apixaban and was 0.42 U/ml after enoxaparin.","A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22398784/),[u] / [ml],1.36,238163,DB01225,Enoxaparin
,22398784,peak pharmacodynamic effect,"Average peak pharmacodynamic effect, measured by anti-Xa activity, was 1.36 U/ml after administration of apixaban and was 0.42 U/ml after enoxaparin.","A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22398784/),[u] / [ml],0.42,238164,DB01225,Enoxaparin
,23227470,plasma activity,"The anti-FXa plasma activity increased significantly after enoxaparin administration, with peak levels at 3 h after treatment, but was comparable between the ICU and medical ward groups (median 0.16 IU ml-1 [IQR 0-0.22 IU ml-1] vs. 0.2 IU ml-1 [IQR 0.15-0.27 IU ml-1],respectively, P = 0.13).",Bioactivity of enoxaparin in critically ill patients with normal renal function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23227470/),[iu] / [ml],0.16,246944,DB01225,Enoxaparin
,23227470,plasma activity,"The anti-FXa plasma activity increased significantly after enoxaparin administration, with peak levels at 3 h after treatment, but was comparable between the ICU and medical ward groups (median 0.16 IU ml-1 [IQR 0-0.22 IU ml-1] vs. 0.2 IU ml-1 [IQR 0.15-0.27 IU ml-1],respectively, P = 0.13).",Bioactivity of enoxaparin in critically ill patients with normal renal function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23227470/),[iu] / [ml],0.2,246945,DB01225,Enoxaparin
,23227470,area under the anti-FXa activity curve from 0–12 h,"The area under the anti-FXa activity curve from 0–12 h was similar between the groups (median 0.97 IU ml-1 h [IQR0.59-2.1] and 1.48 IU ml-1 h1 [IQR 0.83-1.62], P = 0.42 for the ICU group compared with the control group, respectively).",Bioactivity of enoxaparin in critically ill patients with normal renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23227470/),[h·iu] / [ml],0.97,246946,DB01225,Enoxaparin
,23227470,area under the anti-FXa activity curve from 0–12 h,"The area under the anti-FXa activity curve from 0–12 h was similar between the groups (median 0.97 IU ml-1 h [IQR0.59-2.1] and 1.48 IU ml-1 h1 [IQR 0.83-1.62], P = 0.42 for the ICU group compared with the control group, respectively).",Bioactivity of enoxaparin in critically ill patients with normal renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23227470/),[h1·iu] / [ml],1.48,246947,DB01225,Enoxaparin
,12040334,apparent clearance,"The mean apparent clearance, distribution volume, and plasma half-life were 0.733 L/h, 5.24 L, and 5 hours, respectively.",Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040334/),[l] / [h],0.733,252945,DB01225,Enoxaparin
,12040334,distribution volume,"The mean apparent clearance, distribution volume, and plasma half-life were 0.733 L/h, 5.24 L, and 5 hours, respectively.",Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040334/),l,5.24,252946,DB01225,Enoxaparin
,12040334,plasma half-life,"The mean apparent clearance, distribution volume, and plasma half-life were 0.733 L/h, 5.24 L, and 5 hours, respectively.",Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040334/),h,5,252947,DB01225,Enoxaparin
,24810867,Cmax,Following the single SC injection Cmax was 0.83 ± 0.08 anti-Xa IU/mL and in 5/6 cats was detected after 2 h (Tmax = 110 ± 25 min).,Enoxaparin: pharmacokinetics and treatment schedule for cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),[iu] / [ml],0.83,255769,DB01225,Enoxaparin
,24810867,Tmax,Following the single SC injection Cmax was 0.83 ± 0.08 anti-Xa IU/mL and in 5/6 cats was detected after 2 h (Tmax = 110 ± 25 min).,Enoxaparin: pharmacokinetics and treatment schedule for cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),min,110,255770,DB01225,Enoxaparin
,24810867,total clearance,The total clearance was 23.4 ± 4.8 mL/h/kg and the terminal half-life was 2.27 ± 0.4 h.,Enoxaparin: pharmacokinetics and treatment schedule for cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),[ml] / [h·kg],23.4,255771,DB01225,Enoxaparin
,24810867,terminal half-life,The total clearance was 23.4 ± 4.8 mL/h/kg and the terminal half-life was 2.27 ± 0.4 h.,Enoxaparin: pharmacokinetics and treatment schedule for cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),h,2.27,255772,DB01225,Enoxaparin
,24810867,peak,"All cats receiving repeated injections reached the defined target peak range of 0.5-1.0 IU/mL by 2 h after the second injection (0.54 [0.50-0.61]; median, [minimum - maximum]) and there was no considerable accumulation subsequently.",Enoxaparin: pharmacokinetics and treatment schedule for cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),[iu] / [ml],0.5-1.0,255773,DB01225,Enoxaparin
,24810867,activated partial thromboplastin time ratio,"With the exception of thromboelastometry (especially non-activated), ratio values of coagulation times increased significantly although only slightly (e.g., the maximal value of median activated partial thromboplastin time ratio was 1.27).",Enoxaparin: pharmacokinetics and treatment schedule for cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810867/),,1.27,255774,DB01225,Enoxaparin
,29423936,clearance (CLTYP,"Parameter estimates were CLi = CLTYP * (BWPREOP /70)3/4 ; Vi = VTYP * (BW(t)/70)1 ; where typical clearance (CLTYP ) and typical volume of distribution (VTYP ) were 1.23 l h-1 and 14.6 l, respectively.",Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423936/),[l] / [h],1.23,257078,DB01225,Enoxaparin
,29423936,volume of distribution (VTYP ),"Parameter estimates were CLi = CLTYP * (BWPREOP /70)3/4 ; Vi = VTYP * (BW(t)/70)1 ; where typical clearance (CLTYP ) and typical volume of distribution (VTYP ) were 1.23 l h-1 and 14.6 l, respectively.",Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423936/),l,14.6,257079,DB01225,Enoxaparin
,29423936,anti-,More than 100 IU kg-1 12 h-1 are suggested to reach the target range of anti-Xa activity of 0.2-0.4 IU ml-1 from the first day.,Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29423936/),i,0.2-0.4,257080,DB01225,Enoxaparin
,12147872,peak anti-Xa level,"The peak anti-Xa level was 1.30 0.18 IU/ml (range, 1.03 1.69 IU/ml).",Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12147872/),[iu] / [ml],1.30,257917,DB01225,Enoxaparin
,12147872,minimum anti-Xa level,The minimum anti-Xa level was 0.55 IU/ml 4 hours after enoxaparin.,Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12147872/),[iu] / [ml],0.55,257918,DB01225,Enoxaparin
,1963020,half-life,"After intravenous administration, unfractionated heparin was cleared with a half-life of 35 min, irrespective of assay methods.",Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1963020/),min,35,257924,DB01225,Enoxaparin
,1963020,half-life,"However, the concentration of enoxaparin, measured by competitive binding assay, declined with the longer half-life of 60 min, and its anti-Factor IIa and anti-Factor Xa activities had half-lives of 40 and 275 min, respectively.",Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1963020/),min,60,257925,DB01225,Enoxaparin
,1963020,half-lives,"However, the concentration of enoxaparin, measured by competitive binding assay, declined with the longer half-life of 60 min, and its anti-Factor IIa and anti-Factor Xa activities had half-lives of 40 and 275 min, respectively.",Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1963020/),min,40,257926,DB01225,Enoxaparin
,1963020,half-lives,"However, the concentration of enoxaparin, measured by competitive binding assay, declined with the longer half-life of 60 min, and its anti-Factor IIa and anti-Factor Xa activities had half-lives of 40 and 275 min, respectively.",Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1963020/),min,275,257927,DB01225,Enoxaparin
,11011804,MW,"The mean MW of these compounds ranges from 3,600 to 6,500 daltons.",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),daltons,"3,600 to 6,500",267803,DB01225,Enoxaparin
,11011804,retention time,"The mean retention time of aXa activity varies from 5.2 (dalteparin) to approximately 7 h (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),h,5.2,267804,DB01225,Enoxaparin
,11011804,retention time,"The mean retention time of aXa activity varies from 5.2 (dalteparin) to approximately 7 h (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),h,7,267805,DB01225,Enoxaparin
,11011804,Bioavailability,"Bioavailability of prophylactic doses of LMWHs ranges from 86% (dalteparin) to 98% (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),%,86,267806,DB01225,Enoxaparin
,11011804,Bioavailability,"Bioavailability of prophylactic doses of LMWHs ranges from 86% (dalteparin) to 98% (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),%,98,267807,DB01225,Enoxaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],16,267808,DB01225,Enoxaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],21,267809,DB01225,Enoxaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],33,267810,DB01225,Enoxaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],19,267811,DB01225,Enoxaparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],22,267812,DB01225,Enoxaparin
,15995464,peak anti-Xa activity,Mean peak anti-Xa activity was 0.19 +/- 0.09 International Units/mL and mean trough was 0.044 +/- 0.04 International Units/mL.,Optimal dose of enoxaparin in critically ill trauma and surgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15995464/),[international·units] / [ml],0.19,269411,DB01225,Enoxaparin
,15995464,trough,Mean peak anti-Xa activity was 0.19 +/- 0.09 International Units/mL and mean trough was 0.044 +/- 0.04 International Units/mL.,Optimal dose of enoxaparin in critically ill trauma and surgical patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15995464/),[international·units] / [ml],0.044,269412,DB01225,Enoxaparin
,34311154,clearance,The covariate analysis showed that enoxaparin clearance (typical value 1.1 L.h-1) was related to renal function estimated by the CKD-EPI formula and volume of distribution (typical value 17.9 L) to actual body weight.,Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311154/),[l] / [h],1.1,270534,DB01225,Enoxaparin
,34311154,volume of distribution,The covariate analysis showed that enoxaparin clearance (typical value 1.1 L.h-1) was related to renal function estimated by the CKD-EPI formula and volume of distribution (typical value 17.9 L) to actual body weight.,Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311154/),l,17.9,270535,DB01225,Enoxaparin
,34311154,peak levels,Simulation of anti-Xa activities with enoxaparin 40 mg qd indicated that 64% of the patients had peak levels within the range 0.2 to 0.5 IU.,Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34311154/),iu,0.2 to 0.5,270536,DB01225,Enoxaparin
,7586247,maximal peak activity,The maximal peak activity for aPTT ratio was 1.7.,Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586247/),,1.7,271172,DB01225,Enoxaparin
longer,7586247,Disappearance time,Disappearance time of these activities after the highest dose of both LMWHs was longer than 16 hours.,Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586247/),h,16,271173,DB01225,Enoxaparin
,7586247,activity half-life,Overall mean antifactor Xa activity half-life was 4.6 hours.,Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586247/),h,4.6,271174,DB01225,Enoxaparin
